Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

13.85
+0.35002.59%
Pre-market: 13.850.00000.00%07:06 EDT
Volume:2.09M
Turnover:29.33M
Market Cap:2.08B
PE:-3.09
High:14.33
Open:13.60
Low:13.53
Close:13.50
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:0.94
T/O Rate:1.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:170.45
PE(LYR):-2.02

Loading ...

Biohaven Files Form 3 for Chief Legal Officer Warren Karl Volles

Reuters
·
Jul 18

Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer

MT Newswires Live
·
Jul 10

Biohaven’s Bruce Car retires as chief scientific officer

TIPRANKS
·
Jul 10

Biohaven Promotes David Pirman to EVP, Head of Discovery

Reuters
·
Jul 10

Press Release: Biohaven Announces Scientific Leadership Transitions

Dow Jones
·
Jul 10

Analysts’ Top Healthcare Picks: Heart Test Laboratories, Inc. (HSCS), Biohaven Ltd. (BHVN)

TIPRANKS
·
Jul 01

Biohaven announces completion of enrollment in RISE3 trial

TIPRANKS
·
Jun 30

Biohaven - Completes Enrollment in Rise3 Pivotal Phase 2/3 Focal Epilepsy Study with Opakalim

THOMSON REUTERS
·
Jun 30

Biohaven - Top-line Results from Rise3 Study Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 30

Biohaven Completes Enrollment in RISE3 Pivotal Opakalim Focal Epilepsy Trial, Data Due 2H 2026

Reuters
·
Jun 30

Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at Bofa

Dow Jones
·
Jun 30

Biohaven falls -9.8%

TIPRANKS
·
Jun 29

Biohaven Cut to Underperform from Neutral by B of a Securities

Dow Jones
·
Jun 29

BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target

MT Newswires Live
·
Jun 29

Biohaven Starts Pivotal Phase 3 Trial of Bhv-1300 in Graves' Disease

Reuters
·
Jun 29

Biohaven Advances a New Class of Precision Immunology Therapies: First Mode Extracellular Protein Degrader, Bhv-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 29

Biohaven rises 7.4%

TIPRANKS
·
Jun 26

U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex

Reuters
·
Jun 26

Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says

MT Newswires Live
·
Jun 25